As of 2025-04-24, the EV/EBITDA ratio of Arbutus Biopharma Corp (ABUS) is -8.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Arbutus's latest enterprise value is 574.49 mil USD. Arbutus's TTM EBITDA according to its financial statements is -71.22 mil USD. Dividing these 2 quantities gives us the above Arbutus EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.3x - 11.2x | 10.3x |
| Forward P/E multiples | 15.6x - 30.5x | 19.8x |
| Fair Price | (5.60) - (3.98) | (5.41) |
| Upside | -275.5% - -224.9% | -269.5% |
| Date | EV/EBITDA |
| 2025-04-23 | -8.20 |
| 2025-04-22 | -8.07 |
| 2025-04-21 | -8.12 |
| 2025-04-17 | -7.96 |
| 2025-04-16 | -7.72 |
| 2025-04-15 | -7.99 |
| 2025-04-14 | -8.31 |
| 2025-04-11 | -7.93 |
| 2025-04-10 | -7.88 |
| 2025-04-09 | -8.01 |
| 2025-04-08 | -7.23 |
| 2025-04-07 | -7.57 |
| 2025-04-04 | -8.17 |
| 2025-04-03 | -8.93 |
| 2025-04-02 | -8.93 |
| 2025-04-01 | -8.85 |
| 2025-03-31 | -8.87 |
| 2025-03-28 | -8.90 |
| 2025-03-27 | -8.28 |
| 2025-03-26 | -8.50 |
| 2025-03-25 | -8.55 |
| 2025-03-24 | -8.60 |
| 2025-03-21 | -8.31 |
| 2025-03-20 | -8.39 |
| 2025-03-19 | -8.39 |
| 2025-03-18 | -8.09 |
| 2025-03-17 | -8.31 |
| 2025-03-14 | -8.36 |
| 2025-03-13 | -8.42 |
| 2025-03-12 | -8.07 |
| 2025-03-11 | -7.72 |
| 2025-03-10 | -7.85 |
| 2025-03-07 | -8.39 |
| 2025-03-06 | -8.55 |
| 2025-03-05 | -8.79 |
| 2025-03-04 | -8.60 |
| 2025-03-03 | -8.68 |
| 2025-02-28 | -8.77 |
| 2025-02-27 | -8.55 |
| 2025-02-26 | -8.74 |
| 2025-02-25 | -8.77 |
| 2025-02-24 | -8.47 |
| 2025-02-21 | -8.68 |
| 2025-02-20 | -8.74 |
| 2025-02-19 | -8.60 |
| 2025-02-18 | -8.52 |
| 2025-02-14 | -8.34 |
| 2025-02-13 | -8.36 |
| 2025-02-12 | -8.39 |
| 2025-02-11 | -8.39 |